Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01440192 · ClinicalTrials.gov registry record · Phase 1
Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis
A Phase 1 study, sponsored by Celularity Incorporated.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01440192: Clinical Trial Phase 1 study, sponsored by Celularity Incorporated.
NCT01440192 is a Phase 1 study that was terminated before completion, run by Celularity Incorporated. The registered enrollment target is 4 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01440192, a Phase 1 study, was terminated before completion, sponsored by Celularity Incorporated.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The primary objective of the study is to assess the safety and tolerability of a single dose of PDA001 (given twice) in subjects with Stage II or III Pulmonary Sarcoidosis (PS) who are refractory to one or more of the following treatments for PS: methotrexate,immunosuppressants or cytotoxic agents.
Primary Outcome
Evaluate pulmonary artery pressure during infusion
Interventions
- BIOLOGICAL PDA001 (cenplacel-L)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2011-09 |
| Est. Completion | 2014-02 |
| Phase | Phase 1 |
Why NCT01440192 stopped before completion
NCT01440192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which PDA001 (cenplacel-L) is the first listed.
NCT01440192 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01440192 about?
NCT01440192 is a clinical study titled "Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis". The primary objective of the study is to assess the safety and tolerability of a single dose of PDA001 (given twice) in subjects with Stage II or III Pulmonary Sarcoidosis (PS) who are refractory to one or more of the following treatments for PS: methotrexate,immunosuppressants or cytotoxic agents.
What is the current status of trial NCT01440192?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2011-09. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01440192?
The interventions under investigation include: PDA001 (cenplacel-L) (BIOLOGICAL).
Who is sponsoring clinical trial NCT01440192?
This trial is sponsored by Celularity Incorporated, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01440192's enrollment target sits among peer trials
4 1995th of 2000 higher than 2 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia